Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN)

Edith Pituskin, Mark Haykowsky, Margaret McNeely, John Mackey, Neil Chua, Ian Paterson, Edith Pituskin, Mark Haykowsky, Margaret McNeely, John Mackey, Neil Chua, Ian Paterson

Abstract

Background: Cancer is the leading cause of premature death in Canada. In the last decade, important gains in cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also result in cardiovascular "toxicity". Furthermore, cardiac risk factors such as hypertension, dyslipidemia, and diabetes mellitus are known to contribute to the progression of cardiac damage and clinical cardiotoxicity. As such, for many survivors, the risk of death from cardiac disease exceeds that of recurrent cancer. While provision of care by multidisciplinary teams has been shown to reduce mortality and hospitalizations among heart failure patients, the effect of assessments and interventions by multidisciplinary specialists in cancer patients receiving cardiotoxic chemotherapy regimens is currently unknown. Accordingly, we will examine the effect of a multi-disciplinary team interventions in the early assessment, identification and treatment of cardiovascular risk factors in cancer patients receiving adjuvant systemic therapy. Our main hypothesis is to determine if the incidence of LV dysfunction in cancer patients undergoing adjuvant therapy can be reduced through a multidisciplinary team approach.

Methods/design: This is a randomized study comparing intensive multidisciplinary team intervention to usual care in the prevention of LV remodeling in patients receiving anthracycline or trastuzumab-based chemotherapy. Main objectives include early detection strategies for cardiotoxicity using novel biomarkers that reflect myocardial injury, remodeling and/or dysfunction; early identification and intensive treatment of cardiovascular risk factors; and early intervention with supportive care strategies including nutritional and pharmacist counselling, exercise training and cardiology team support. Secondary objectives include correlation of novel biomarkers to clinical outcomes; correlation of multidisciplinary interventions to adverse clinical outcomes; relationship of multidisciplinary interventions and chemotherapy dose density; preservation of lean muscle mass; and patient reported outcomes (symptom intensity and quality of life).

Discussion: Cardiac toxicity as a result of cancer therapies is now recognized as a significant health problem of increasing prevalence. To our knowledge, TITAN will be the first randomized trial examining the utility of multidisciplinary team care in the prevention of cardiotoxicity. We expect our results to inform comprehensive and holistic care for patients at risk for negative cancer therapy mediated sequelae.

Trial registration: ClinicalTrials.gov, NCT01621659 Registration Date 4 June 2012.

Keywords: Breast cancer; Cardiac dysfunction; Heart failure; Lymphoma; Multidisciplinary.

Figures

Fig. 1
Fig. 1
Flow chart TITAN Study

References

    1. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(31):4952–4960. doi: 10.1200/JCO.2006.08.0499.
    1. Anand SS, Yusuf S: Stemming the global tsunami of cardiovascular disease. The Lancet. 2011;377(9765):529–32.
    1. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50(15):1435–1441. doi: 10.1016/j.jacc.2007.06.037.
    1. Wells QS, Lenihan DJ: Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cardiovasc Dis. 2011;53(2):140–48.
    1. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(2):277–281. doi: 10.1093/annonc/mdg070.
    1. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672–1677. doi: 10.1001/jama.1991.03470120074036.
    1. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults. J Clin Oncol. 2004;22(10):1864–1871. doi: 10.1200/JCO.2004.06.033.
    1. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Increased perioperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer. Circulation. 2007;115(11):1339–1344. doi: 10.1161/CIRCULATIONAHA.106.647008.
    1. Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, et al. Cardiovascular Risk Profile of Patients with HER2/neu-Positive Breast Cancer Treated with Anthracycline-Taxane-Containing Adjuvant Chemotherapy and/or Trastuzumab. Cancer Epidemiol Biomark Prev Pub Am Assoc Canser Res Am Soc Prev Oncol. 2007;16(5):1026–1031. doi: 10.1158/1055-9965.EPI-06-0870.
    1. Jones LW, Haykowsky M, Pituskin EN, Jendzjowsky NG, Tomczak CR, Haennel RG, et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor—positive operable breast cancer. Oncologist. 2007;12(10):1156–1164. doi: 10.1634/theoncologist.12-10-1156.
    1. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med. 2006;57:485–498. doi: 10.1146/annurev.med.57.121304.131240.
    1. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–3131. doi: 10.1161/01.CIR.0000133187.74800.B9.
    1. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25(25):3859–3865. doi: 10.1200/JCO.2006.09.1611.
    1. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–7819. doi: 10.1200/JCO.2005.02.4091.
    1. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol. 2007;7(2):61–66. doi: 10.1007/s12012-007-0016-2.
    1. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2011;55(3):213–20.
    1. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–2019. doi: 10.1016/S0140-6736(07)61865-0.
    1. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–344. doi: 10.1038/nrc2106.
    1. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4–10. doi: 10.1634/theoncologist.12-S1-4.
    1. Janjan NA, Cleeland CS. Pain and suffering during cancer therapy: continued sins of omission. Int J Radiat Oncol Biol Phys. 2008;72(1):6–8. doi: 10.1016/j.ijrobp.2008.05.048.
    1. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22(17):3485–3490. doi: 10.1200/JCO.2004.03.025.
    1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847. doi: 10.1161/01.CIR.97.18.1837.
    1. Lenihan DJ. Tyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork? J Clin Oncol. 2008;26(32):5154–5155. doi: 10.1200/JCO.2008.18.5439.
    1. Lenihan DJ, Esteva FJ. Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer. Oncologist. 2008;13(12):1224–1234. doi: 10.1634/theoncologist.2008-0112.
    1. Hung C, Daub B, Black B, Welsh R, Quinney A, Haykowsky M. Exercise training improves overall physical fitness and quality of life in older women with coronary artery disease. Chest. 2004;126(4):1026–1031. doi: 10.1016/S0012-3692(15)31272-1.
    1. Haykowsky M, Vonder Muhll I, Ezekowitz J, Armstrong P. Supervised exercise training improves aerobic capacity and muscle strength in older women with heart failure. Can J Cardiol. 2005;21(14):1277–1280.
    1. Mackey DC, Manini TM, Schoeller DA, Koster A, Glynn NW, Goodpaster BH, Satterfield S, Newman AB, Harris TB, Cummings SR et al.: Validation of an Armband to Measure Daily Energy Expenditure in Older Adults. J Gerontol A Biol Sci Med Sci. 2011;66(10):1108–13.
    1. Carlson LE, Bultz BD. Cancer distress screening. Needs, models, and methods. J Psychosom Res. 2003;55(5):403–409. doi: 10.1016/S0022-3999(03)00514-2.
    1. Fadol A, Mendoza T, Gning I, Kernicki J, Symes L, Cleeland CS, et al. Psychometric testing of the MDASI-HF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail. 2008;14(6):497–507. doi: 10.1016/j.cardfail.2008.01.012.
    1. Bruera E, Kuehn N, Miller MJ, Selmser P, MacMillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.
    1. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GBJ, Mcpherson R, et al. Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2012;29(2):151–167. doi: 10.1016/j.cjca.2012.11.032.
    1. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, et al. Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2015;31(5):549–568. doi: 10.1016/j.cjca.2015.02.016.
    1. Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007;28(2):69–73. doi: 10.1097/MNM.0b013e328025ae04.
    1. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med. 2007;357(1):94–95. doi: 10.1056/NEJMc070065.
    1. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–2481. doi: 10.1161/CIRCULATIONAHA.106.635144.
    1. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2000;2(4):271–278.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics. 2011;42(2):377–81.
    1. Alberta Cancer Research Biobank [)]. Accessed March 2016.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi